How to Help Your Patients Find Depo-Estradiol in Stock: A Provider's Guide

For providers who prescribe estradiol cypionate injection, the discontinuation of brand-name Depo-Estradiol has created a new layer of administrative and clinical complexity. Patients are calling your office confused, prescriptions are being rejected at pharmacies, and the search for compounding solutions takes time that neither you nor your patients have. This guide is designed to streamline the process — giving you practical tools to help your patients access the medication they need with minimal disruption.

The Core Problem: Why Patients Are Getting Stuck

When a patient arrives at a retail pharmacy with a prescription for Depo-Estradiol, they're met with one of two responses: 'We don't carry that product' or 'That's been discontinued.' Neither response comes with much guidance on what to do next.

The challenge is systemic: compounded medications are not stocked by chain pharmacies. Without a compounding pharmacy referral and a correctly written prescription, patients cannot fill their medication. Many patients don't know what a compounding pharmacy is, let alone how to find one. This creates an access gap that your practice can help close.

Step 1: Update Your Prescription Template

The single most impactful action your practice can take is updating your electronic health record (EHR) prescription templates. Remove or archive any templates that write 'Depo-Estradiol' by brand name and replace them with:

Estradiol Cypionate Injection (Compounded), 5 mg/mL in cottonseed oil, 5 mL vial, intramuscular injection, [dose and frequency based on indication]

Include a prescriber note indicating the medication should be dispensed from a compounding pharmacy. Some EHR systems allow you to specify a preferred pharmacy — use this to direct patients to your preferred compounding pharmacy relationship.

Step 2: Build a Compounding Pharmacy Referral List

Create a one-page handout listing 2-4 compounding pharmacies — both local and mail-order — that your practice has vetted and trusts. For each pharmacy, include:

Pharmacy name and address (or website for mail-order)

Phone number and best time to call

Whether they ship nationally (for 503B facilities)

Typical cash pricing for compounded estradiol cypionate 5 mg/mL, 5 mL vial

PCAB accreditation or 503B registration status

Quality criteria to use when vetting compounding pharmacies: PCAB accreditation (for 503A), FDA registration and compliance history (for 503B), USP 797 sterile compounding compliance, and availability of Certificate of Analysis (CoA) for each batch.

Step 3: Use medfinder for Providers to Help Patients Search

Rather than having your staff spend time on hold with pharmacies, direct patients to medfinder for Providers. medfinder contacts pharmacies on behalf of the patient to determine which ones can fill the specific prescription — including compounding pharmacies for specialty medications like estradiol cypionate. Results are typically delivered within 24 hours.

This can save your front desk team significant time and reduce the number of callbacks you receive from frustrated patients who can't find their medication.

Step 4: Provide Backup Formulation Prescriptions

For patients at higher risk of treatment interruption — those in rural areas, patients with limited transportation, those on fixed incomes — consider providing a backup prescription at the same appointment. The backup prescription should be for an alternative estrogen formulation that the patient can fill if compounded estradiol cypionate is temporarily unavailable.

Appropriate backup options by patient type:

Menopausal patients: Oral estradiol (widely available, low cost) or estradiol gel (EstroGel, Divigel)

Hypogonadism patients: Estradiol valerate injection (compounded or generic Delestrogen) or oral estradiol

Transgender patients (GAHT): Estradiol valerate injection or oral/sublingual estradiol as a bridge

Step 5: Proactively Contact At-Risk Patients

Run a report in your EHR for all active patients with a current prescription for Depo-Estradiol or estradiol cypionate injection. Send a proactive communication — portal message, letter, or phone call — to inform them of the brand discontinuation, what it means for their prescription, and what to do next.

Sample patient communication language:

'We're writing to let you know that Depo-Estradiol (estradiol cypionate injection) has been discontinued by its manufacturer, Pfizer. Your medication is still available through compounding pharmacies. We have updated your prescription accordingly. Please call our office at [phone] so we can send your updated prescription to a compounding pharmacy near you or arrange mail-order delivery.'

Monitoring After Transition to Compounded Estradiol Cypionate

When a patient transitions from the brand-name product to a compounded version, serum estradiol levels should be monitored after 4-8 weeks to confirm therapeutic adequacy. While the active ingredient is the same, differences in carrier oil, concentration, and compounding technique may affect absorption variability.

Target ranges for monitoring:

Menopausal symptom management: trough estradiol 40-100 pg/mL

Gender-affirming HRT (GAHT): estradiol 100-200 pg/mL, testosterone <50 ng/dL (per Endocrine Society guidelines)

Hypogonadism: target to restore physiologic estradiol levels appropriate for age and reproductive goals

Summary Checklist for Your Practice

Update EHR templates to write compounded estradiol cypionate injection

Create a compounding pharmacy referral handout for patients

Direct patients to medfinder for Providers to help locate pharmacies

Provide backup formulation prescriptions at appointments

Proactively notify all active estradiol cypionate patients of the situation

Schedule serum estradiol monitoring 4-8 weeks after any formulation transition